Donald Trump is expected to sign an executive order on defining biological sex on reproductive cells rather than gender ...

In the article that accompanies this editorial, Bartlett et al 11 present the results of ECHELON-3, a phase III trial comparing brentuximab vedotin + lenalidomide + rituximab (BV + Len + R) with ...

CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition ...

Adult patients with R/R DLBCL with eligible subtypes, including transformed DLBCL, were enrolled. Patients must have received ≥2 previous lines of systemic therapy, be ineligible for hematopoietic SCT ...